Manufacturing

1. Combining Expertise With Best-In-Class Technology 10/20/2021

   Members of the MilliporeSigma leadership team reflect on the longstanding experience of our BioReliance® viral vector manufacturing facilities. Our legacy experience, alongside our brand new facility and latest industry innovations, ensure we are a preferred partner to pioneer the path to cures.

2. Factors Which Impact mAb Process Scale-Up 9/7/2021

   Thinking about your mAb scale-up processes early on can help avoid common pitfalls. Cytiva’s Fast Trak scientists discuss factors that can influence a successful scale-up outcome.

3. Mycap® Bottle Closures – Aseptic Fluid Transfer Systems For Bottles 9/6/2022

   The innovative MYCAP bottle closure system provides more options for aseptic fluid transfer in bottles and rigid containers. The elastomeric closure makes it a truly universal closure system.

4. What Is Causing Limited Bioavailability 4/21/2025

   Discover how this label-free whole-body QMSI combined with plasma LC-MS/MS can help identify the root causes of limited bioavailability and guide smarter optimization strategies early in development.

5. Cell Therapy Bioprocessing Workflow Cinematic 5/28/2025

   Witness a seamless cell therapy bioprocessing workflow that reduces manufacturing time and preserves the crucial cell phenotype for scalable, effective autologous and allogeneic therapies.

6. Connect And Disconnect Aseptically Using Sterile Connection Technology 5/18/2022

   In this video, we review how assembling is a quick and easy three-step process - flip, click, and pull. See how to follow these steps to ensure a secure, leak-free connection.

7. MilliporeSigma Large Scale Capabilities Tour 10/20/2021

   A detailed look at MilliporeSigma’s new BioReliance® viral vector manufacturing facility and how we have employed the latest innovations and quality systems to deliver best-in-class gene therapy services.

8. Executive Roundtable: Cell Therapy Predictions For 2025 And Beyond 12/17/2024

   In this executive roundtable discussion, Bioprocess Online editor Tyler Menichiello is joined by CEO, co-founder, and president of Ossium Health, Kevin Caldwell, CSO of FibroBiologics, Hamid Khoja, Ph.D., and president and acting CEO of Triumvira Immunologics, Rob Williamson. The panelists share their predictions and thoughts on the industry’s direction heading into 2025. They cover manufacturing trends (noting opportunities for improvements in cell therapy manufacturing), AI adoption, regulatory concerns, and the potentially challenging funding environment ahead. 

9. DynaDrive Single-Use Bioreactors Drilled-Hole Sparge Technology 3/30/2026

   Uniform bubble size and consistent mass transfer across scales through drilled-hole sparge technology improves oxygen delivery and CO2 stripping in demanding cell culture processes.

10. Introducing Our Single Use Mixing System 11/3/2022

    Ross Acucena, applications director, and Donnie Beers, product manager, introduce our single-use mixing system made to be deployed rapidly to help manufacturers meet development, supply, and cost objectives.